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Abstract: Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is 
characterized by bone brittleness and various degrees of growth disorder. Clinical severity 
varies widely; nowadays eight types are distinguished and two new forms have been recently 
described although not yet classified. The approach to such a variable and heterogeneous 
disease should be global and therefore multidisciplinary. For simplicity, the objectives of 
treatment can be reduced to three typical situations: the lethal perinatal form (type II), in 
which the problem is survival at birth; the severe and moderate forms (types III–IX), in which 
the objective is ‘autonomy’; and the mild form (type I), in which the aim is to reach ‘normal 
life’. Three types of treatment are available: non-surgical management (physical therapy, 
rehabilitation, bracing and splinting), surgical management (intramedullary rod positioning, 
spinal and basilar impression surgery) and medical-pharmacological management (drugs to 
increase the strength of bone and decrease the number of fractures as bisphosphonates or growth 
hormone, depending on the type of OI). Suggestions and guidelines for a therapeutic approach 
are indicated and updated with the most recent findings in OI diagnosis and treatment.
Keywords: osteogenesis imperfecta, bone genetic disorder, bone brittleness, “brittle bone 
disease”, connective tissue malfunction, short stature, progressive skeletal deformities, blue 
sclerae, dentinogenesis imperfecta, joint laxity, adult onset deafness
Introduction
Osteogenesis imperfecta (OI), also known as “brittle bone disease”, is the most  common 
genetic bone disorder and its prevalence is estimated around 1 in 10,000–20,000 births. 
OI is characterized by evidence of connective tissue malfunction and its clinical pre-
sentation is extremely variable: affected individuals are susceptible to fractures from 
the mildest trauma; reduced bone mass; varying degrees of short stature; progressive 
skeletal deformities; blue sclerae; dentinogenesis imperfecta; joint laxity; and adult 
onset deafness.1,2 The clinical heterogeneity of OI ranges from death in the perinatal 
period, through marked short stature and severe bone deformity, to normal life expec-
tancy with only mild osseous fragility and slightly decreased bone mass; the prognosis 
and the achievement of walking and autonomy are greatly influenced by the number 
of fractures and deformities and the age at which they begin. Clinical severity varies 
widely and nowadays eight types are distinguished;3,4 the types initially delineated 
by Sillence are: type I mild non-deforming; type II perinatal lethal; type III severely 
deforming; and type IV moderately deforming.5 In recent years four more types have 
been added: type V moderate to severe disease often causing deformity and short 
stature, with normal teeth and sclera; type VI moderate disease with severe vertebral 
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body involvement with compression, white or blue sclera, 
normal teeth and no wormian bones; type VII that clinically 
is similar to type II although with smaller head and white or 
faintly blue sclera; type VIII that is similar to type III although 
with a round face, normal sclera and barrel shaped chest;6 
and type IX, which is milder than types VII and VIII.7 The 
prognosis is mainly influenced by the degree of bone fragility, 
whose severity increases in the order: type I , types IV, V, 
VI, ,type III, VII, VIII , type II.
The great majority of OI cases (almost 90%) are caused 
by heterozygosity of dominant mutations in one of the two 
genes (COL1A1 and COL1A2) encoding the chains of type 
I collagen,8,9 with quantitative (mild or moderate forms) or 
qualitative (severe or lethal forms) defect of the  synthesis of 
type I collagen.10 Other involved genes are those encoding for 
cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 
1 and cyclophilin B, that form an intracellular collagen-
modifying complex that 3-hydroxylates proline at position 
986 in the alpha 1 chains of collagen (type I, II and V). Muta-
tions in these essential cofactors cause alterations in the post-
translational chain modification and collagen folding that are 
responsible for autosomal recessive lethal or severe OI: type 
VII,11–13 type VIII and type IX.7,14,15 An additional recessive 
form (possibly type X?) with a very severe  phenotype has 
been described, due to homozygosity for a missense mutation 
in the serine proteinase inhibitor, clade H.16 This gene encodes 
for the collagen chaperone heat shock protein 47, which is 
involved in proper collagen folding. Probably other disease 
causing genes will be found for rare recessive OI forms; it 
should also be considered that types V and VI etiologies are 
still unknown.
Treatment of OI depends on the severity of the disease 
and on the age of the patient; in any case a treatment strat-
egy should provide the maximum of long-term function and 
autonomy.17–19 For simplicity, the objectives of treatment can 
be reduced to three typical situations (Table 1): the mild form 
(type I), in which the aim is to reach ‘normal life’; the severe 
and moderate forms (types III–IX), in which the objective is 
‘autonomy’; and the lethal perinatal form (type II), in which 
the problem is survival at birth.
The approach to such a variable and heterogeneous  disease 
should be global and therefore multidisciplinary, such as the 
one adopted by the Italian Multidisciplinary Study Group 
for OI.17 Patients and their relatives meet quarterly to yearly 
(depending on the patient’s age and needs) with  specialists 
working on different aspects of OI in different centers in 
Italy: pediatricians, orthopedists,  physiotherapists, geneticists 
and biochemists, occasionally joined by an  otologist and a 
dentist. The clinical data, supported by radiographic and 
photographic images, are recorded on a centralized electronic 
database. This approach is particularly advantageous for 
the patients and their families, since they obtain first-hand 
advice from different specialists at the same time regarding 
diagnosis, prognosis and particular therapeutic decisions 
such as surgical intervention. Moreover, with such a rare 
disease, this is the only approach that enables the recruitment 
of extensive experience and a sufficient cohort of patients to 
perform controlled therapeutic trials.
Treatment of mild form (type I)
In a child presenting one or more unexplained fractures 
without a familial history of OI, it is sometimes difficult 
to differentiate a mild form of OI (type I and especially 
type IV with white sclerae) from non-accidental injury, 
juvenile idiopathic osteoporosis or the debated ‘temporary 
brittle bone disease’.20,21 In little children the lateral x-ray of 
spine is a basic element to evaluate bone osteoporosis. In 
unclear cases, after clinical and radiological studies, further 
diagnostic information may be obtained from bone mineral 
density (BMD) and from the measurement of bone metabolic 
markers, morphological and ultrastructural bone studies, 
and biochemical and molecular collagen studies. BMD is 
generally decreased in OI patients,22 and dual energy x-ray 
absorptiometry (DXA) of the lumbar spine or of the whole 
body may help to establish the diagnosis. In some cases, and 
particularly in the first year of life, there is a considerable 
degree of overlap between individuals with OI and normal 
values.23,24 In children and adults with mild OI with a quan-
titative type I collagen synthesis defect (type I OI), some 
metabolic markers of bone apposition (eg, carboxyterminal 
propeptide of type I procollagen are clearly lower than in 
normal controls. Genetic testing can be done by DNA testing 
(molecular study), on peripheral blood or on saliva speci-
mens, or looking at the protein expression of type I procol-
lagen (biochemical studies), on cultured fibroblasts from a 
skin biopsy. While routine biopsy or blood molecular study 
for children suspected to have been abused are unwarranted,25 
biochemical and molecular studies could be useful in the 
differentiation between qualitative and quantitative collagen 
I defects (Table 1).
OI type I patients rarely develop significant deformities 
and almost all achieve ambulation. The required care is 
mainly for periodic fractures or for associated problems, 
such as erosion of the teeth, impaired hearing and diffi-
culties in adjustment. The goal in OI type I patients, both 
children and adults, is to have a ‘normal life’, lowering the 
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risk of fractures and increasing bone density. A child with 
OI type I must be strongly encouraged to have a normal 
life, with normal schooling, although avoiding the high 
risk traumatic activities and sports. A supervised training 
program is fundamental together with improving aerobic 
capacity and muscle force reduces levels of subjective 
fatigue in children with OI type I and IV in a safe and 
effective manner.26 Problems during childhood may be short 
stature and fractures. Short stature is relatively uncommon 
in OI type I children, although a difference from other 
unaffected family members may pose some psychological 
problems. Disproportion between trunk and lower limbs 
is a frequent sign of platispondilia reducing the global 
height. Joint hyperlaxity may occur in OI type I with severe 
Table 1 Problems and objectives of treatment in three typical situations of osteogenesis imperfecta (Oi)17
Problems Goals Possible solutions
OI mild form (type I)
Children
Decreased bone strength  
and high fracture frequency
increase bone strength  
and decrease fracture frequency
Rehabilitation for correct motor and psychological 
development and after fractures (intramedullary 
rods in some patients)
increase BMD or collagen synthesis Bisphosphonate treatment 
Growth hormone or other growth factors
Attain ‘normal life’ Correct job choice 
Avoid traumatic activities
Short stature increase stature Growth hormone or other growth factors
Adults
Hearing loss Reduce hearing loss or normalize  
acoustic function
Hearing aids 
Stapes surgery 
Cochlear implantation
Decreased bone strength  
and high fracture frequency
increase (or avoid decrease)  
of bone mineral density
Bisphosphonate treatment
OI severe-moderate forms (types III–IX)
Children
Decreased bone strength, high fracture  
frequency, bone deformities
increase bone strength  
and decrease fracture frequency
intensive rehabilitation program  
intramedullary roding in the majority of patients
increase bone mineral density Bisphosphonate treatment
Absence of autonomy Reach the maximum of autonomy  
possible in the particular patient
Assure adequate aids at home and the possibility 
of autonomy outside (motorized wheelchair)
Progressive kyphoscoliosis  
and reduced ventilatory capacity
Reduce or stop the progression  
of kyphoscoliosis. Ameliorate  
respiratory function
Corsets (?) 
Surgical intervention 
Monitoring oxygen saturation, possibility  
of oxygen therapy at home
Short stature increase stature Cautious use of growth hormone or other 
growth factors
Adults
Hearing loss Reduce hearing loss or normalize  
acoustic function
Hearing aids 
Stapes surgery 
Cochlear implantation
Adulthood osteoporosis increase bone mineral density Bisphosphonate treatment
OI lethal perinatal (type II)
Pre and perinatal fractures Reduce number of fractures Surgical intervention 
Adequate management 
Special beds, bivalve corsets
Respiratory insufficiency Assure supportive therapy 
Treat respiratory infections 
(secondary to abnormal ventilation)
ventilatory assistance 
Antibiotic treatment
Cardiorespiratory failure Resuscitation maneuvers
Failure to thrive Adequate caloric intake enteral feeding
information for parents Prenatal diagnosis in families with an affected child 
Genetic counseling
Abbreviations: Oi, osteogenesis imperfecta; BMD, bone mineral density.
Therapeutics and Clinical Risk Management 2010:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
370
Monti et al
instability in the knees and feet. Mainly in these patients, 
walking parameters are modified with hip  extrarotation, knee 
hyperextension, and flat foot with extrarotation is much more 
evident in cases of overweight patients. Fractures are treated 
when possible in a conservative way by standard casts as 
those used in patients without OI. When a fracture occurs 
twice or more on the same level surgical treatment with an 
intramedullary nail is needed. Repeated fractures may pose 
problems of frequent periods of absence from school and 
the need for rehabilitation and motor recovery after each 
negative event. During adulthood problems may be osteo-
porosis (which in women may worsen during gestation and 
lactation,27 and after menopause with an increased fracture 
frequency, mainly of the spine) and hearing loss may also 
occur after the second and third decades.
As for medical treatment, all patients must have an 
adequate vitamin D intake (400–800 U/day) and a regular 
dietary calcium intake (800–1000 mg daily during infancy) 
and this may be obtained through an ordinary diet or through 
calcium and/or vitamin D supplements; the decision of start-
ing bisphosphonates (BPs) and/or growth hormone (GH) 
treatment (Table 1) must be evaluated in each case.
Patients with OI have a precise follow-up protocol that 
provides an evaluation of the clinical and  biochemical 
 condition (the number of fractures, calcium and other 
nutrient intake, physical activity and clinical symptoms 
related to the disease eg, skeletal or respiratory) and in 
growing patients auxological parameters as weight, height, 
body mass index, height velocity and Tanner staging need 
to be evaluated also. Bone metabolic parameters (urinary 
Ca, P-Phosphate and Creatinine together with serum Ca, 
P, alkaline  phosphatase, parathyroid hormone (PTH), 
25-hydroxyvitamin D,  osteocalcin, C-terminal cross-linking 
telopeptides of type I collagen, insulin-like growth factor-I, 
(IGF-I) and also routine biochemistry, including creatinine) 
are evaluated twice a year, while bone mass measurements 
(measured by DXA) are performed once or twice a year, 
depending on severity and age of patients. From childhood to 
adulthood, the lateral x-ray of the spine is a useful screening 
follow up, particularly in women from premenopausal age: 
for a precise evaluation of thoracic area of the spine (that it 
is not studied by DXA) it is suggested should be performed 
at least every two years.
In patients with dentinogenesis imperfecta a stringent 
odontoiatric and orthodontic assessment is important  during 
the first years of age; we usually perform the first check 
when the baby teeth are set, and subsequent assessment 
is decided on needs although usually around 4–6 years of 
age when all teeth are sealed. The major complications, 
fracture and  excessive wear of fragile teeth, can be treated 
by capping teeth with hard polymers in order to coat and 
shape them.28–30 The aim of treatment is to avoid infective 
complications (eg, pulpitis or abscesses) and to prevent 
facial deformities due to the loss of teeth (or parts of them) 
and malocclusion.
Hearing loss, a very common complication in OI,31 can 
be managed initially by hearing aids, although it frequently 
requires surgery to replace the ossicular structures. We 
usually suggest the detection of hearing problems after 
puberty and periodically (eg, every 5–10 years) in adulthood. 
Replacement of the fractured and fused bones of the middle 
ear has provided significant restoration of hearing for many 
affected individuals.32 However, it is questionable whether 
stapes surgery will be as successful in OI types other than 
type I, some groups have recently claimed that the surgical 
treatments, indicated under current international criteria, 
could eventually obtain limited functional results.33 In the 
past, a progressive sensorineural hearing loss arising as a 
result of progression in the disease process, independently 
of surgery, appears to have a severe influence on the final 
hearing threshold.34 For this reason, cochlear implantation 
has been performed in cases of OI and the results are similar 
to implant outcomes in patients with sensorineural hearing 
loss from a variety of other causes.35
Treatment of progressively 
deforming, moderately severe forms 
(type III, IV, V, VI, VII, VIII, IX)
OI diagnosis in the great majority of cases is  straightforward, 
on the basis of clinical and radiological findings; further 
 diagnostic information can be obtained from BMD and 
 measurement of bone metabolic markers, from  morphological 
and ultrastructural bone studies as well as from biochemical 
and molecular studies. DNA analysis is considered a better 
test for diagnosis as compared with dermal biopsy;36 how-
ever, it has to be said that genetic testing alone cannot rule 
out OI. Nearly 10% of mutations in collagen I are missed 
by current techniques and OI types V–VIII, as well the two 
new forms not yet classified, are due to mutations in different 
genes, and, as the molecular studies can be quite lengthy, an 
experts’ opinion is fundamental. The differentiation between 
 qualitative and quantitative collagen I defects, obtained 
through biochemical and molecular studies is an important 
issue in view of the prognosis and medical therapeutic 
options, and it encourages collagen experts to try to define 
the phenotype-genotype correlations.
Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
371
Treating osteogenesis imperfecta
In individuals with type III to VIII OI there is sometimes 
an overlap with normal values. Conversely, markers of bone 
resorption, such as the serum c-terminal telopeptide region 
of type I collagen, are elevated in severely affected patients 
with a qualitative defect.37 In cases where the diagnosis is 
difficult, a bone biopsy can help to confirm OI, and will be 
diagnostic for OI types V and VI, whose genetic basis is 
still unknown.
The clinical treatment of children and adults with severe 
OI is a difficult challenge for physicians and other people 
caring for them. The therapeutic objective therefore should 
be to provide the best long term function and autonomy that 
the disease allows: to minimize fractures; deformities and 
disability; to reduce pain; to maintain comfort; for the patient 
to achieve relative independence in the activities of daily 
living and mobility; and to enhance social integration. The 
attainment of these goals requires a multidisciplinary team 
approach in order to tailor treatment needs to the severity of 
the disease and the age of the patient.38
The care plan involves the patient, the family and the 
community, together with the medical and nursing staff. 
 Collaboration between the medical team (essentially 
 pediatrician, orthopedist and physiotherapist) and the  family 
is especially important in each phase of the treatment, 
with complete information and candid discussion on the 
 therapeutic options. Medical staff should help both patients 
and families to develop a realistic attitude toward their life 
and future plans. They should also assure the family that an 
OI child can be educated to become a self-supporting adult. 
Therefore, the family should be encouraged to see that the 
OI child attends regular school classes, whenever possible, 
and so reaches the maximum possible intellectual and aca-
demic development. Many patients will become productive 
members of society, so the combination of optimal physi-
cal and mental development will offer more chances for a 
satisfactory life.
Children are generally psychologically well compensated 
during childhood, when acceptance, sociability and a certain 
adaptation to the disease are present. A psychologist (both 
for the adolescence and for the family) has sometimes to 
be consulted when problems, principally related to a young 
person’s confidence and the body image become evident 
during adolescence. Generally, however, the discomfort 
tends to be alleviated if the adolescent with OI is able to 
maintain as much contact as possible with his/her peers at 
school and in the social environment. Overprotection is to 
be discouraged and relationships with healthy adolescents 
should be encouraged.
During the first months it is important to try to avoid 
spinal deformities, maintaining a semi-sitting position over 
a stiff padded seat. This allows the child to have visual 
contact with the environment and makes breathing more 
comfortable. In infancy the prevention and treatment of 
respiratory  infections with respiratory rehabilitation and 
resolute antibiotic therapy are helpful. In the case of a fracture 
parental intervention is fundamental, as the limb has to be 
immobilized as soon as possible.
Three types of treatment are available:
•	 Nonsurgical management (physical therapy,  rehabilitation, 
bracing and splinting)
•	 Surgery (intramedullary rod positioning, spinal and 
basilar impression surgery)
•	 Drugs to increase the strength of bone and decrease the 
number of fractures (eg, BPs and GH).
Nonsurgical management
Nonsurgical management aims at: preventing and treating 
fractures; at enhancing motor development; muscle strength 
and a range of joint motion; at preventing contractures and 
deformities due to position; at improving functional ability 
and locomotion; at correcting malalignment of the lower 
extremity joints that prohibit weight bearing; and developing 
compensatory strategies. The approach starts with an evalu-
ation of motor development and function,39 the identification 
of functional needs,40 the selection of near and long term 
objectives, and the development of a program consistent 
with reaching them, including the use of orthotic devices.41–43 
The rehabilitation approach is more easily followed during 
a period in a specialized ward. On discharge from hospital a 
program of physiotherapy treatment should be continued at 
home with the aid of specialist personnel and full coopera-
tion of the parents. The approach consists of initial handling 
and positioning followed by functional and formal strength-
ening exercises. At the beginning, after lower extremity 
surgery, it is better to perform treatment in water: here it 
is possible to walk with minor pain, as the water reduces 
load bearing and the natural resistance of the water may 
improve muscle strength. The maintenance of good muscle 
tone and  respiratory exercise are essential.26 Swimming and 
in-water exercises are indicated in non-ambulatory patients, 
to improve the sense of balance and, as a result of an absence 
of weight, to gain otherwise impossible movement.
Undisplaced fractures are treated by standard orthopedic 
measures appropriate for the age of the patient and the type 
of fracture. Fracture healing is not impaired in OI and an 
immobilization time longer than normal is not required. 
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Bone fragility may be aggravated by osteoporosis subsequent 
to immobilization, which derives from an antalgic posture, 
supine obligatory decubitus and splinting. The vicious circle 
of fracture, immobilization, osteoporosis and refracture must 
be interrupted. Use of plaster casts needs to be minimized and 
the use of traction and mobile splints has to be implemented, 
since stimulating muscular function and forcing early weight 
bearing, they produce a stress to the lower limb bones that is 
essential for bone trophism. Progressive improvement in bone 
strength during adolescence permits better eventual func-
tion for patients in whom good skeletal alignment has been 
maintained. Patients who have been confined to a wheelchair 
may start walking. The possibility of autonomy at this stage 
is inversely correlated to the severity of  damage and defor-
mities, especially to the spine and lower limbs accumulated 
in preceding years.
Surgery
To prevent and/or correct long-bone deformities that impair 
function and to decrease fracture frequency, to provide more 
functional anatomy of the extremities, properly timed opera-
tions for insertion of intramedullary rods, together with sup-
portive splints and braces, may be performed.44–46 The need for 
intervention is more frequent for femurs and tibiae, whereas 
fixation of the humerus is less often undertaken,47 and in the 
forearm intervention is rarely indicated. As for anesthesia, 
precautions should be taken for the possible cervical fragil-
ity during intubations and close monitoring during surgery is 
essential because of the association of malignant hyperthermia 
with OI,48 even if recent findings conclude that this relation 
seems weak.49 Studies with gait analysis have been done in 
a group of walking patients with OI studying hip rotation 
patterns and global flexion of lower limbs before and after 
surgical treatment. This evaluation may be useful in planning 
surgery and energy consumption in different patterns of walk-
ing, with or without orthosis and other aids.50 In children older 
than 2 years, until significant linear growth persists, surgical 
orthopedic intervention includes multiple osteotomies and the 
use of intramedullary telescopic rods. These rods, following 
the bone growth, last for longer than non-elongating rods and 
need less frequent changing. However, they require a more 
complex surgical procedure and seem to increase osteoporosis 
of limb bones. In this procedure, a correct placing of the upper 
extremity of the nail, near the inner part of grand trochanter, 
may reduce the high frequency of femoral neck varus which, 
if it appears, would need a later specific surgical correction 
(most frequently in prepubescent age groups). With percutane-
ous non-extensible intramedullary rods, early stable fixation 
can be provided for patients too young and/or too sick for 
definitive or extensive open surgery, or in cases of near final 
growth.51 Flexible intramedullary rods have specific contrain-
dication in growing OI children although they can be used in 
young OI adults with good cortical bone. The choice between 
elongating or non-extensible rods has to be taken with regards 
to each particular patient and in the particular situation, on the 
basis of the surgeon’s experience. Complications with the use 
of expanding intramedullary rods in patients with OI are fre-
quent,52 and the risk is higher in patients aged less than 5 years, 
and when rods are placed in the tibia rather than the femur.53 
In Italian and French procedures tibial extensible rods have 
now been replaced by two steel nails with the single extremity 
flexed in a L fashion to permit elongation. The major compli-
cation is rod migration, often combined with the perforation 
of joints, bone and soft tissue, Further fractures may occur, 
although in such cases rods prevent displacement, reduce 
healing time and the requirement for splints or plaster casts. 
Despite a high rate of complications, intramedullary tele-
scopic rods have proven to be the most successful treatment 
for prevention and correction of fractures and deformities of 
the long bones, improving walking ability and leading to the 
successful rehabilitation of even severely affected patients.54–56 
Moreover, intramedullary rods in the lower extremities before 
the age of 3.5 years enhances neuromotor development.57 After 
surgery, immobilization should be strictly limited to the time 
necessary for healing; then the rehabilitation process should 
continue, since surgical treatment has not to be considered as 
an isolated intervention. Surgical intervention has to be seen 
in a comprehensive view, as a stage in a psychomotor and 
rehabilitative route starting before and continuing beyond the 
event. A comprehensive, aggressive physical therapy rehabili-
tation program and long leg bracing58 with surgical operations 
on the femur, result in a high level of functional activity for 
children with OI that is associated with an acceptable risk level 
for future fractures that brings children into graded exercise 
regimes and fosters their increased involvement in school and 
social situations.59 Unfortunately, autonomous ambulation is 
beyond the  capability of some affected individuals because of 
bone fragility and deformities. In these cases the purpose of 
treatment is to provide some mobility at home, while outside 
the home electrically powered wheelchairs provide a certain 
degree of autonomy.
Spinal deformity is common and causes difficulty in 
sitting, pain and potentially life-threatening complica-
tions. Scoliosis is difficult to treat with external bracing 
because of the compliant nature of bones and the tendency 
to rib  deformation. Early bracing, although somewhat 
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effective, may well compress the soft osteoporotic rib cage 
with little or no effect on the progression of the curve.60,61 
 Therefore pulmonary compromise created by scoliosis may 
be  compounded by chest cage deformity secondary to brac-
ing. Soft bracing can help in reducing back pain and lumbar 
kyphosis and improves postural balance while sitting. Even 
if it may not be correlated to other district involvement, in 
OI patients scoliosis severity is usually characterized by a 
high degree of stiffness of the spine and for this reason the 
possibility of its reduction is low post-puberty. In case of 
a scoliosis of 30° Cobb in OI patients aging 11–12 years, 
a 6 monthly x-ray and clinical follow-up is needed. If 
progression is evident then surgical intervention (with a 
mean of 40 days in halo traction) has to be performed and 
it must be followed by spinal stabilization (with or without 
instrumentation) and by a mean one month period with a 
cast. In case of major curves or of an extended delay waiting 
for surgery (over 15 years) the results may be less effective. 
However, if the procedure is undertaken on time, the scoliosis 
can be ameliorated with curve stabilization, an improve-
ment in respiratory function and the relief of back pain.62 
In patients with severe scoliosis and/or basilar impression, 
whose respiratory function may be insufficient, there is often 
a need for the control of nocturnal respiratory parameters 
and supporting oxygen therapy or continual ventilation.63 In 
patients with mild disease (thick bones and few fractures) 
treatment should be similar to that of patients with idio-
pathic scoliosis. Basilar impression may become clinically 
significant and complicated by compression, syrinx forma-
tion, hindbrain herniation and symptomatic obstruction with 
hydrocephalus requiring neurosurgical intervention. Patients 
may require ventricular shunt placement or posterior fossa 
or transoral-transpalato-pharyngeal decompression followed 
by occipito-cervical fusion. However, despite successful 
fusion basilar invagination tends to progress and only pro-
longed external orthotic immobilization (particularly during 
adolescence) is required to stabilize symptoms and arrest 
progression of the deformity.64–66
Medical treatment
Medical treatment should always be considered as part of 
a coordinated multidisciplinary approach to the treatment 
of children with OI, including timely corrective surgery, 
physiotherapy and occupational therapy.
Until a gene therapy directed towards either replace-
ment or silencing of the mutant allele is feasible, the causal 
defect of the disease cannot be corrected. At present, medical 
therapy to treat the causal defect is not possible, although 
some ‘symptomatic’ treatment options are available. The 
goals of pharmacological therapy in OI are: to decrease 
the incidence of fractures; to increase growth velocity; to 
decrease pain; to have a positive effect on bone metabolic 
markers; bone histomorphometry and BMD; and finally 
to increase mobility and independence. All of these are 
important outcome parameters, although they are not simple 
to measure accurately and reproducibly in children with 
severe OI. As in other rare diseases, the conduction of a 
therapeutic study protocol is accompanied by the difficulty 
to enroll a large number of patients comparable for sex, age, 
height and clinical severity; moreover because of the extreme 
variability in the clinical severity of OI, each child usually 
has a different clinical history and has undergone different 
kinds of pharmacological, rehabilitative and orthopedic 
personalized treatments that may also influence growth. 
Eventually at puberty there is a notable decrease in fracture 
frequency and the relative stabilization of deformities, thus 
the positive results of any therapy may not be distinguished 
from the positive effects of sex hormones at this age. 
Only in recent years has the use of bone density measure-
ment by DXA provided a method to study objectively and 
reproducibly a parameter linked to bone strength and the 
possibility of monitoring the response to different types of 
treatment.22 In growing individuals bone mineral content 
(BMC) and BMD tend to increase, these results have to be 
corrected for bone volume.23,24 All these facts may limit the 
possibility of evaluating the efficacy of a therapy conducted 
for a sufficiently long period in a large group of patients. 
High expectations often accompany the use of new drugs in 
OI, although these prospects are often disappointing in the 
long term management of OI.67
During past decades various systemic pharmacologi-
cal agents have been administered to patients with OI and 
the majority of them initially claimed beneficial results, 
although none proved effective in controlled trials.68 
Among these were anabolic steroids, vitamin D, vitamin C, 
sodium fluoride, magnesium oxide, flavonoids (catechin) 
and calcitonin. Until 18 years ago, calcitonin was the most 
common therapy for OI, although its beneficial effects dur-
ing the clinical course of the disease were disputed in the 
literature,69 now however it is no longer used. In severe and 
moderately severe OI (generally due to a structural defect of 
type I collagen synthesis) agents increasing the production 
of type I collagen, such as GH, do not represent a suitable 
treatment, other agents that reduce bone resorption, such as 
BPs, are preferable for their action in increasing BMC. A 
combined GH-BPs treatment regimen seems to be, at least 
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theoretically, a possible pathogenic approach, since it would 
couple the stimulation of bone apposition by GH with the 
inhibition of bone resorption by BPs. However, possible 
candidates should be selected very carefully for such com-
bined therapy. Eventually, since the PTH is a potent bone 
anabolic agent, shown to reduce the incidence of fractures 
in postmenopausal osteoporosis,70 it seemed to be a suitable 
candidate for OI treatment; however, because of its possible 
collateral effects (young rats receiving PTH subsequently 
developed osteosarcoma71) it shouldn’t be used in children 
before resolving these issues.
Treatment of lethal perinatal OI 
(type II)
Type II OI has to be differentiated from other forms of lethal 
skeletal dysplasias (thanatophoric dysplasia, achondrogenesis 
and the autosomal recessive form of hypophosphatasia). 
When diagnosis of a lethal (or severe) form of OI is made 
prenatally and the decision is taken to complete the preg-
nancy, all measures to offer supportive care must be taken 
and parental bonding is encouraged. Cesarean delivery is 
requested whenever obstetric complications are suspected, 
however, this does not prolong the survival of infants with 
the lethal form of OI and does not affect either the fracture 
rate per infant or the number of infants with fractures among 
those with the nonlethal OI phenotypes.72
In prenatally undiagnosed cases therapeutic decisions 
must often be taken when the diagnosis is still unclear 
and the neonate has marked respiratory insufficiency. The 
decision to start ventilatory assistance and other supportive 
care is often difficult, with the risk of using excessively 
aggressive therapy. In fact, more than 60% of infants with 
OI type II die within the first 24 hours, and 80% die within 
the first month, survival beyond a year is extremely rare. 
Cardiorespiratory insufficiency and respiratory infections 
are the most common cause of death in these children, their 
prevention and treatment are important factors for prognosis. 
Because of respiratory insufficiency, many of these infants 
have feeding problems, and it is only with continuous enteral 
feeding that adequate caloric intake can be maintained. At 
home, the few infants that can leave hospital, always need 
supportive care. Parents should be instructed to manage the 
infant, to recognize when a fracture occurs and to treat it with 
cautious immobilization. Bedding that contains soft foam 
or water, can decrease the frequency of fractures. Frequent 
changing of the infant’s head position can avoid cranial 
deformation, and in some cases that of spinal deformity, a 
bivalve brace may be helpful.
Since mosaic carriers of OI mutations experience mild 
to no clinical symptoms it seems that even a minor fraction 
of normal osteoprogenitor cells may have significant clinical 
benefits,73 attempts at bone marrow transplantation (BMT) 
have been undertaken in children affected by OI74–77 and even 
if they produced a low engraftment rate there were surprising 
and interesting symptomatic improvements. Horwitz and col-
leagues reported 1%–2% engraftment in children with OI, 
but an increase in BMC by DXA. Intrauterine transplantation 
(IUT) may be even more promising: Le Blanc and colleagues 
achieved 7% engraftment after IUT of fetal liver donor cells, 
although the potential phenotypic effects were masked by bis-
phosphonate administration,78 While promising, the results of 
these clinical trials are difficult to interpret because of various 
limitations such as a lack of matched controls, interference 
of other contemporaneous treatment and unfeasibility of 
evaluating engraftment beyond a single biopsy site.
Bisphosphonates
BPs have been accepted as the standard of care for children 
with OI and in particular with moderate to severe forms of 
OI. However, questions remain as to: the selection of patients 
for treatment, which BPs should be used, what the minimum 
effective dose and the minimum effective treatment interval 
should be, what the appropriate duration of treatment should 
be and what the role of oral BPs are.
The BP compounds are analogs of pyrophosphate which, 
when administered either orally or parenterally, are character-
ized by a rapid and strong binding to hydroxyapatite crystals in 
the bone mineral. Once BPs are buried in the skeleton they are 
released only when bone is destroyed in the course of bone 
turnover. These agents are potent inhibitors of bone resorp-
tion, decreasing osteoclast activity and number, although 
some effect on bone formation also occurs.79 This activity 
results in improved vertebral shape and mass, higher cortical 
width, increased cancellous bone volume and suppressed 
bone turnover as shown by histomorphometric studies.80 
The net effect is to promote bone mineral accretion and at 
the same time to reduce bone turnover. Several compounds 
with different relative potency for inhibiting bone resorption 
are used in humans. Derivatives with an amino group at the 
end of the side chain (pamidronate was the first described) 
are very active.81 Reported possible adverse effects with the 
intravenous administration of BPs are a slight lowering of 
serum calcium levels, which are rarely symptomatic, and 
transient high fever. With oral administration some gastro-
intestinal adverse effects and non-uniform absorption and 
bioavailability have been reported.82
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Wide experience of the use of BPs has been gained 
in adults for the treatment of involutional osteoporosis, 
Paget’s osteitis deformans, bone pain and hypercalcemia 
of malignancy. In contrast, experience with BPs in children 
with various pathologies, such as juvenile osteoporosis, has 
been limited until recently and most of the current reports 
refer to small numbers of patients.83–86 Following limited 
early studies,87,88 several researchers have demonstrated that 
oral (olpadronate89,90 and alendronate91,92) or intravenous 
(pamidronate93–101 and neridronate102,103) BP treatment has 
a beneficial effect on children with severe OI.104 In a large 
non-controlled observational study involving 30 children 
(aged 3 to 16 years) with severe OI, Glorieux and colleagues 
demonstrated that the cyclic administration of intravenous 
pamidronate improved clinical outcomes, decreased the 
incidence of fractures, reduced bone resorption, increased 
bone density and the size of vertebral bodies.97 They also 
showed that the treatment did not alter the rate of fracture 
healing, neither the growth rate, nor the appearance of the 
growth plates, such that mobility and ambulation improved 
or remained unchanged and that all the children reported 
substantial relief of chronic pain and fatigue. In addition, 
even in severely affected OI patients under 3 years of age, 
pamidronate treatment is well tolerated, increases BMD 
and decreases their fracture rate.105 Cyclical BP treatment 
markedly suppresses bone turnover and, after some years, 
seems to reach the maximum of its beneficial effect.100 
However, in growing patients treatment discontinuation leads 
to the construction of a low density metaphyseal bone tissue 
(added by longitudinal growth) that is probably responsible 
for zones of localized bone fragility in comparison to the 
tissue created during treatment.106 Despite unanswered ques-
tions concerning them, BP treatment does appear to have 
a strong positive effect on the morbidity of severe forms 
of OI and it seems reasonable to continue the treatment 
more extensively.107 These studies93–103 reported encourag-
ing results and strongly indicate that BPs are useful in the 
symptomatic treatment of children with severe OI, moreover 
without serious adverse effects. As with earlier studies these 
current trials share a common limitation, namely they are 
all open trials, therefore these favorable results should be 
confirmed in double-blind controlled studies.
In a congenital disease such as OI, it appears logical to 
start treatment as early as possible. Indeed, promising results 
were reported in patients who received BPs in the first years 
of life.80,103,105 When treatment is being considered, since the 
knowledge of the long term tolerability is very limited and 
not all countries have BP therapy authorized in children, after 
the treatment regimen is explained, it may be necessary for 
an informed consent to be obtained from the parents and, if 
appropriate, from the child. As for the choice of BP, there 
are groups that treat OI patients (including children with 
moderate to severe OI) with cyclical intravenous pamidronate, 
in cycles of three days, repeated every 2 to 4 months (with 
an annual dose of 9 mg/kg/year).97,98 In our experience any 
advantage in terms of duration of treatment results from the 
cyclical intravenous administration of neridronate (which is 
the only BP authorized in children with OI in Italy) received 
as an infusion over 3 hours in a single day (the dose is 
subdivided in two days in children younger than 3 years) and 
is generally repeated every 3 months (with an annual dose of 
8 mg/kg/year).102,103 Zoledronic acid (an infusion given over 
45 minutes for one day) has been recently used108 although 
it is still undergoing clinical trials, in infants.
Growth hormone
In mild forms of OI, agents increasing the production of type 
I collagen may have a therapeutic role. GH action positively 
affects bone growth and bone turnover by stimulating 
osteoblasts, collagen synthesis and longitudinal bone 
growth.109 As part from this positive action on bone, GH has 
a positive action on collagen metabolism, stimulating the 
expression in osteoblast cultures of IGF-I and IGF binding 
protein-3, which in turn regulate the synthesis of type I 
collagen.110,111 Osteoblasts from various species have IGF-I 
receptors and respond to both endogenous and exogenous 
IGF by accelerating the proliferation, increasing DNA and 
collagen synthesis.112,113 On the other hand, animal studies in 
the mouse model of OI, with bone phenotype comparable to 
a mild form of OI in humans (oim/+), showed that systemic 
GH injections114 or GH transgene expression in erythroid 
marrow115 increased spine and femur length, produced sig-
nificant changes in densitometric parameters and ameliorated 
biomechanical structural properties of bone.
GH could be used in OI either for stimulating bone 
metabolism,116 increasing in particular bone apposition, 
or for increasing statural growth, since growth deficiency 
is constantly present in severe OI and common in mild to 
moderate forms of the disease.117 GH-somatomedin axis 
activity has been studied in children with OI and hypoactivity 
of this axis (without a true GH deficit) was found in 
approximately half of the patients studied.118 In other studies 
IGF-I serum levels were mostly found in the low normal 
physiological range.117,119 There is limited literature regarding 
GH experience in OI as only a few human studies have been 
performed using GH in patients with OI.118,120 Studies on 
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calcium (Ca) kinetics have shown that more Ca was available 
for bone mineralization following GH treatment.121
Two types of approach have been attempted in the 
GH treatment of OI, one is an extensive, general stimulus 
of bone metabolism, the other, based on more stringent 
criteria, stimulates collagen synthesis in cases of ascertained 
quantitative deficiency. One of the first attempts to treat OI 
with GH was carried out more than 20 years ago by Kruse 
and Kuhlencordt, who treated two patients affected by OI 
with GH. The patients had an increase in periosteal new 
bone formation and in intracortical bone resorption (assessed 
using histomorphometry of bone biopsies), with enhanced 
relative osteoblastic activity.122 Following these results, no 
further study was reported in the literature until Marini and 
colleagues published their preliminary results from a limited 
number of patients treated with GH or clonidine (a pituitary 
GH secretagogue).118 In a further study by this group, the 
authors concluded that there is a group of type IV OI children 
who would benefit from GH treatment in terms of linear 
growth, bone matrix synthesis and bone histomorphometric 
parameters.123 Sillence and colleagues showed a positive 
height growth, an increase in skeletal volume and in BMD 
and infer that the subsequent reduction in fracture frequency 
appears to confer a significant therapeutic benefit.124 During 
GH therapy patients have an improvement in general well-
being, muscular performance and motor ability, and this 
increases physical activity and consequently fracture risk in 
some cases.125 Strict rehabilitative therapy may contribute 
to preventing fractures, together with an adequate calcium 
and phosphate intake during treatment. Our group evaluated 
the efficacy of 1 year of GH treatment (0.2 mg/kg/week in 
6 divided doses) in patients affected by type I OI with an 
ascertained quantitative defect in type I collagen synthesis. 
GH treatment showed a positive action on bone turnover, 
markers of bone apposition (ie, osteocalcin and procollagen 
type I carboxyterminal propeptide levels) and BMD increased 
significantly, while the fracture risk did not change. The 
growth rate was significantly higher in treated patients than in 
the pre-treatment period and in the untreated group. Further-
more, protein anabolic effects of GH resulted in an increase 
of both muscle mass and strength, which, in combination 
with GH-related improvements in exercise capacity and 
cardiac performance, may increase physical activity with the 
concomitant beneficial effects on skeletal integrity.126 These 
promising results led to a continuation of this GH study in a 
second group of patients and the results indicated that this is 
a useful therapy in patients with moderate forms of OI (the 
majority of type I and a good proportion of type IV), where it 
has demonstrated a beneficial effect on bone turnover, BMD 
and height velocity, without increasing the fracture risk in 
the short term. Patients with pre-existing scoliosis or bone 
deformities must be treated with particular caution because 
of the potential risk of worsening of these problems. Patients 
with severe OI (type III and a subset of type IV) do not seem 
to gain any substantial advantage from this therapy. There-
fore, the selection of patients for GH treatment on the basis of 
biochemical and molecular studies is a key factor. Nowadays 
it can be used by experts in selected cases or in clinical trials, 
whereas the routine use in patients with quantitative collagen 
defects must be confirmed with long term studies, in order to 
clarify the possible long term effects. Indeed, in the case of a 
mutation causing structural alterations in the type I collagen 
molecule, leading to an incorporation of the altered molecule 
within the matrix, GH treatment must be proceed with cau-
tion. When treatment is considered, informed consent needs 
to be obtained from the parents and, when appropriate, from 
the child. The physician must clearly explain that OI is not 
an approved indication for GH therapy, that the experience 
with GH in OI is of limited duration, with studies no longer 
than 2 years, and that knowledge of the long term effects is 
very limited.
Future therapies
OI is a genetic disorder, transmitted both in an autosomal 
dominant (predominantly) or recessive manner, that causes 
a quantitative or qualitative defects in the synthesis of the 
structural protein type I. In case of quantitative collagen I 
defects (as nonsense, frame-shift or splicing mutations) this 
leads to a null allele (haploinsufficiency). The final result is 
a reduced synthesis (approximately half that of normal) of 
structurally normal procollagen chains, producing a mild 
to moderate phenotype. In the case of qualitative collagen 
defects (ie, a structural alteration in the type I collagen 
molecule), mutations (typically glycine substitutions) in the 
collagen genes are associated with more severe or lethal 
phenotypes. In these cases abnormal chains are synthesized 
and assembled together with normal chains into collagen 
trimers. Folding of the triple helix is delayed and thus causes 
over modification along the chains. Over modified trimers 
are partially retained within the endoplasmic reticulum (ER), 
causing ER stress and are partially secreted (although less 
efficiently than normal) from the cell and incorporated into 
the extracellular matrix. In the extracellular matrix their 
presence impairs the normal functions of connective tissue to 
a greater degree than a quantitative defect (dominant negative 
effect). In the recessive forms, caused by deficiencies of the 
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3-hydroxylation process, which involves CRTAP, P3H1 and 
cyclophilin B, over modification of type I collagen and the 
consequent intra and extracellular distress are also found 
despite structurally normal α1(I) and α2(I) chains being 
synthesized.14
It was thought that the future of medical treatment for 
this disease lay in the development of gene therapy directed 
towards either replacement or silencing of the mutant allele, 
to correct the causal defect of the disease.127 OI murine 
models (oim, brtl IV, crtap−/−, Mov-13, OASIS−/−), which 
harbor mutations previously characterized in patients, have 
been developed. Currently, these models are being used to 
investigate gene and cell therapies.
Antisense suppression therapy aims to selectively 
decrease or silence the expression of the mutant allele, 
without interfering with the expression of the normal allele, 
and thus biochemically transform a severe form of OI into 
a mild form.128–130 The use of short oligodeoxynucleotides131 
has not lead to encouraging results, in particular the moderate 
successes, the short half-life of unmodified antisense 
oligonucleotides and the toxicity associated with chemical 
modification. An alternative approach to treat dominant 
negative disorders, is the use of hammerhead ribozymes132 
(short RNA molecules with catalytic potential) that could 
eliminate the target sequence (by cleavage), however, the 
problem here is to achieve a sufficient suppression and to 
be introduced in the target cells in a stable way. Another 
molecular tool, RNA interference,133 orchestrated using small 
double-stranded RNA molecules termed siRNAs, is used to 
achieve sequence-dependent suppression of gene expression. 
Limitations common to all the various antisense techniques 
(short oligodeoxynucleotides, ribozymes, silencing RNA) 
used were the lack of true specificity against the mutant 
transcript and the difficulty having stable expression of the 
antisense molecules. It should be stressed that this type of 
therapy will have to be specific for each mutation, making 
this approach unfeasible for OI considering the high number 
of different molecular defects. The possibility to target com-
mon polymorphism linked to the causative mutation seems 
more appealing, providing new hope for a truly clinical 
application. Thus gene therapy is currently limited to in vitro 
or ex vivo studies.
In the case of the structural defect of the collagen apart 
from gene therapy the other chance is molecule replacement 
of cells carrying the mutant gene with normal cells, essentially 
by BMT. The goal of BMT (of marrow stromal cells or more 
recently of mesenchymal stem cells) is to engraft sufficient 
normal cells to normalize tissue function. After a study 
in a murine model of OI,134 Horwitz and colleagues have 
reported initial results of allogeneic BMT in three children 
with OI.74 Three months after osteoblast engraftment (1.5% 
to 2.0% donor cells), representative samples of trabecular 
bone showed histological changes that were indicative of 
new bone formation. All patients had increases in total body 
BMC, in growth velocity and had a reduced frequency of 
bone fracture. The authors concluded that allogeneic BMT 
could lead to engraftment of functional mesenchymal pro-
genitor cells, indicating the feasibility of this strategy for 
OI treatment. This report led to some criticism, and several 
points have been debated; such as the contrast between the 
low level of osteoblast engraftment achieved and the dramatic 
changes reported in skeletal parameters,135 or the difficulty in 
interpreting the decrease in fracture rate at the particular age 
of the patients. Moreover, it has been observed that technical 
difficulties in the evaluation procedures (bone biopsy, BMD 
measurements) in these patients may have jeopardized the 
quality of the data.136 More recently, the exploitation of 
mesenchymal stem cells with the ability to differentiate into 
bone cells has been explored both in vitro and in vivo. The 
BrtlIV OI mouse model has been used for IUT137 and this 
research demonstrated that even a low percentage of normal 
engrafted cells in bone is responsible for the synthesis of a 
good percentage of collagen matrix (over 20%) ameliorating 
the homogeneity of bone mineral matrix, improving bone 
geometry and the biomechanical properties. Obviously, 
moving from mice to human, clinical evaluation should be 
rigorous, since the procedure of BMT is potentially hazard-
ous and may be irreversible. The availability of a matched 
donor is also a challenge to be taken in consideration. Only 
extensive studies in carefully selected patients will indicate 
whether such therapies are the optimal treatment for children 
with severe OI.
Further investigations are currently in progress to 
identify forms of medical therapy that will decrease mor-
bidity in OI.
Conclusions
OI diagnosis is usually made by experts, through a  clinical 
and radiological basis. BMD could be useful in mild forms, 
whereas DNA analysis should not be considered as a 
 diagnosis test, because of lengthy, non-perfect sensibility 
and because of economic considerations. A multidisciplinary 
team approach is essential not only for diagnosis and commu-
nication with patient and parents but also to tailor treatment 
needs to the severity of the disease and the age of the patient. 
The objective of therapy should be to provide the maximum 
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long term function and autonomy that the disease allows. The 
plan of care involves patient, family, medical and nursing 
staff, and community. It involves a combination of nonsur-
gical management and rehabilitation, surgery and medical 
treatment. Currently, the causal defect of the disease cannot 
be corrected with medical treatment and only symptomatic 
therapy is available. GH is beneficial in patients with mild 
forms of the disease. BPs are considered the gold standard of 
treatment for moderate and severe OI forms, since they are 
beneficial in the treatment of symptoms, increasing BMD, 
decreasing fracture rate and reducing pain, without adverse 
effects. An aggressive rehabilitative approach associated 
with intramedullary telescopic roding has been shown to 
improve walking capability. Surgical treatment in patients 
with progressive spinal deformity and in those with basilar 
impression is useful in decreasing the rate of complication.
In the near future therapy will be still based on BPs, since 
GH and BPs protocols are in an advanced phase of research. 
Concomitant GH and BPs therapy, or at least on cyclic 
regimens of these agents, will have to be more frequently 
used rather than using GH alone, as a substitute for other 
drugs. Eventually, future treatment will probably consist of 
cell therapies that aim to biochemically transform a severe 
form of OI into a mild form. Even if there are many technical 
difficulties to overcome, it is hoped that these therapies will 
become available for patients in the not too distant future.
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